2014 End Of Year Update
Happy Holidays and New Year. With your help and unwavering support we achieved many major milestones in 2014. Our accomplishments:
- Accepted into Y Combinator’s W14 batch and we presented at Y Combinator’s S14 demo day. Thank you to the Y Combinator family for your advice, guidance and support.
|Reid presenting at Y Combinator’s demo day. Photo Credit: Silicon Valley Business Journal.|
- Named one of the top 25 most audacious companies changing the world by Inc. and included in the Silicon Valley 100 by Business Insider.
- Successfully completing a ground breaking crowd funding campaign to fund our experiments. Thank you again for supporting us. We wouldn’t be here today without you.
- Our manuscript covering our historical mice experiments was peer-reviewed and published in Vaccine. Review our manuscript here.
- Dr. David Heckerman from Microsoft Research published his manuscript covering the machine learning approach we are using to identify specific targets on the HIV virus preferred by HIV controllers in Journal of Virology. This manuscript makes the clear case that targeting is the specific method that HIV controllers use to defeat the virus. Furthermore Dr. Heckerman was able to identify these targets in a fully computerized / dry lab model. Review his manuscript here.
- We attempted three rounds of testing in two variations of mice and failed. Review details on our mice experiments here.
And we are delighted to share the following major updates with you:
- We attempted to vaccinate human blood in a novel in-vitro model that we designed. These experiments are complicated. There are over 1,000 unique steps for each subject tested in our final experimental design. We tried many different methodologies and eventually discovered one that works. The final result: we were able to successfully show that we can repeatedly vaccinate human blood in-vitro and that vaccinated human blood kills a statistically significant percentage of HIV infected cells.Our results were promising enough for us to present our data at a major HIV focused conference in South Africa called HIV R4P. We invite you to view our data and results here.
|Craig, Reid, and Sarah in South Africa at HIV R4P Conference.|
- We are in discussions with an experienced HIV investigator in Brazil regarding a partnership for a Phase I/II human clinical trial for our vaccine candidate.
As always, please feel free to reach out to team@ImmunityProject.org if you have any questions.
When we launched our campaign last January we set out to do something that no one had done before. With your generous support, we funded and completed more experiments in the past year than organizations with exponentially more funding and resources. We are proud to announce that we successfully met our goal and completed everything we set out to do in our crowd funding campaign. Thank you for giving us the opportunity to run these experiments and validate that the ImmunityProject HIV vaccine prototype has potential.
We aren’t stopping here. We are now focused on raising the funds necessary to finance a Phase I/II human clinical trial for our vaccine prototype. We are ready for this big step now. To do this we need your help. We will be launching a new fundraising program early in the new year for our human clinical trials, but we would like to ask for your help with getting us started. Together we can take the next major step towards a free HIV vaccine for everyone.
Immunity Project exists because of you. Our team wouldn’t be able to do the work that we do without your help and support. Thank you to Nora and the incredible team at Until There’s A Cure for believing in us.
Thank you to Y Combinator for your support, advice and guidance. And thank you to all of our supporters for your generosity and for giving us the opportunity to make Immunity Project happen. Wishing you a happy, healthy and prosperous 2015.
– Reid and Naveen